Siemens Exhibits Intelligent and Integrated Portfolio of IVD Solutions at AACC Clinical Lab Expo
|
By LabMedica International staff writers Posted on 27 Sep 2021 |
|
Siemens Healthineers (Erlangen, Germany) exhibited its intelligent, integrated range of IVD solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held in Atlanta on September 26-30.
AACC's annual meeting is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries. At this year’s AACC, Siemens highlighted its Atellica Solution range of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The Atellica Solution is comprised of sample management, as well as immunoassay and chemistry analyzers, and is an excellent fit for mid-and high-volume labs. It delivers unprecedented flexibility to adapt to changing testing needs and space constraints. The company demonstrated how its Atellica Integrated Automation (AIA) on the Atellica Solution consolidated revolutionary sample management technology, intelligent software, and IT to provide workflow efficiency with the flexibility to add decapping with little or no additional footprint.
Siemens also demonstrated its new, more-scalable automation solutions that include pre- and post-analytics for labs of all sizes to accommodate their specific needs, testing volumes, and resources. Siemens showed how labs could achieve open, one-touch, end-to-end testing with Aptio Automation; Drive open, one-touch sample preparation for multidisciplinary labs with its Atellica Task Targeted Automation; and streamline lab’s biggest chemistry and immunoassay workloads with the Atellica Integrated Automation
Siemens also introduced its new Atellica Hematology Portfolio that pairs analyzers and automation with intelligence to streamline operations and support accurate clinical decision-making that’s on-time, every time. The company displayed two new flagship hematology analyzers - Atellica HEMA 570 and 580 – that are designed to deliver reliable performance targeted for high volume routine workloads.
Siemens is currently developing the Atellica CI 1900 System for the lower-to-mid-volume laboratories. It is planned to utilize the same menu, reagents, consumables, and detection technology as the Atellica Solution2. The Atellica CI 1900 System1 is being designed to take the lab a step beyond by offering the same workflow and IT across the network with the goal of redefining standardization.
Related Links:
Siemens Healthineers
Latest Clinical Chem. News
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Urine Test Diagnoses Early-Stage Prostate Cancer
Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors.... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
Technology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
